Get the Stockscreener App
4.16
2.12%
-0.09
After Hours:
4.25
0.09
+2.16%
Intensity Therapeutics Inc stock is traded at $4.16, with a volume of 22,351.
It is down -2.12% in the last 24 hours and down -12.97% over the past month.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
See More
Previous Close:
$4.25
Open:
$4.5304
24h Volume:
22,351
Relative Volume:
0.57
Market Cap:
$11.24M
Revenue:
-
Net Income/Loss:
$-10.69M
P/E Ratio:
-0.5874
EPS:
-7.0818
Net Cash Flow:
$-9.07M
1W Performance:
+0.24%
1M Performance:
-12.97%
6M Performance:
-52.32%
1Y Performance:
-33.97%
1-Day Range:
$4.16
$4.5304
1-Week Range:
$3.995
$4.5304
52-Week Range:
$3.51
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
4.16 | 12.35M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intensity Therapeutics Inc Stock (INTS) Latest News
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Stock Price, Quote & Chart - ChartMill
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
New patients dosed with INT230-6 in Swiss trial for aggressive triple-negative breast cancer - Pluang
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Intensity Therapeutics restarts 61-patient breast cancer trial - grafa.com
Intensity Therapeutics resumes patient dosing in Swiss trial - Investing.com
Intensity Therapeutics resumes patient dosing in Swiss trial By Investing.com - Investing.com Canada
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
Intensity Therapeutics (INTS) Surges 6.6%: Testing Key Resistance After Strong SessionInverse ETF Flow - dars.gov.et
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Intensity Therapeutics (INTS) Edges Lower, Testing Key Support at $3.91RSI Oversold Picks - dars.gov.et
Form 4 Intensity Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer - Stock Titan
Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount - Stock Titan
Intensity Therapeutics updates INT230-6 cancer trials - grafa.com
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - PR Newswire
Price to sales forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to book forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to earnings forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Enterprise value to EBITDA forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS) - TradingView
Enterprise value to revenue forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
INTS Forecast — Price Target — Prediction for 2027 - TradingView
Intensity Therapeutics Inc (INTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Intensity Therapeutics Inc (INTS) Institutional Confidence - TradingKey
Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting - The Globe and Mail
Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intensity Therapeutics Inc (INTS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com Nigeria
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):